Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus-Reference-Cited by-同舟云学术

Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus

Published:2020-08-20 Issue:9 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

De Pablo-Bernal Rebeca S.¹,Jimenez-Leon M. Reyes¹,Tarancon-Diez Laura¹,Gutierrez-Valencia Alicia¹,Serna-Gallego Ana¹,Trujillo-Rodriguez Maria¹,Alvarez-Rios Ana I.²,Milanes-Guisado Yusnelkis¹,Espinosa Nuria¹,Roca-Oporto Cristina¹,Viciana Pompeyo¹,Lopez-Cortes Luis F.¹,Ruiz-Mateos Ezequiel¹^ORCID

Affiliation:

1. Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, CSIC, University of Seville, Seville, Spain

2. Department of Clinical Biochemistry, Virgen del Rocío University Hospital, CSIC, University of Seville, Seville, Spain

Abstract

The activation phenotypes and functional changes in monocyte subsets during hepatitis C virus (HCV) elimination in HIV/HCV-coinfected patients were evaluated. Twenty-two HIV/HCV-coinfected patients on suppressive combination antiretroviral treatment (cART) achieving HCV elimination after direct-acting antiviral (DAA) therapy and 10 HIV-monoinfected patients were included. The activation phenotype (10 markers) and polyfunctionality (intracellular interleukin-1α [IL-1α], IL-1β, IL-6, IL-8, tumor necrosis factor alpha [TNF-α], and IL-10 production) in three monocyte subsets (classical, intermediate, and nonclassical) were evaluated by flow cytometry before and at the end of treatment.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00773-20

Reference36 articles.

1. A changing paradigm: management and treatment of the HCV/HIV-co-infected patient

2. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras

3. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

4. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome

5. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people;Journal of Virology;2023-12-21

2. Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy;Biomedicine & Pharmacotherapy;2023-06

3. HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy;Scientific Reports;2022-03-24